Novartis AG ADR Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 158 trades in Novartis AG ADR (NYSE: NVS) since 2014, across 25 members, worth an estimated $3M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 81 buys against 76 sells, a modestly buy-led skew, with Democratic members responsible for 48% of the trades and Republican members 52%. The most recent disclosure shown was filed April 2026, and Lisa Mcclain has filed the most NVS transactions among those shown, with 20. Other recent filers include Ro Khanna. One notable disclosed move was a purchase by Lisa Mcclain on June 17, 2025, up 27.2% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Novartis AG ADR (NVS) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Novartis AG ADR congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | |
|---|---|---|---|---|---|---|---|
 Ro Khanna House | Apr 7, 2026 | Mar 13, 2026 | 25 days | SELL |  $1,001 - $15,000 | -6.37% | |
Ro Khanna House | Mar 9, 2026 | Feb 13, 2026 | 24 days | SELL | $1,001 - $15,000 | -9.24% | |
 Lisa Mcclain House | Nov 24, 2025 | Oct 31, 2025 | 24 days | SELL | $1,001 - $15,000 | +19.58% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 31, 2025 | 21 days | SELL | $1,001 - $15,000 | +19.58% | |
Lisa Mcclain House | Nov 24, 2025 | Oct 30, 2025 | 25 days | BUY | $1,001 - $15,000 | +20.73% | |
Lisa Mcclain House | Nov 24, 2025 | Oct 30, 2025 | 25 days | SELL | $1,001 - $15,000 | +20.73% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | SELL | $1,001 - $15,000 | +20.73% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | BUY | $1,001 - $15,000 | +20.73% | |
Lisa Mcclain House | Oct 23, 2025 | Sep 25, 2025 | 28 days | SELL | $1,001 - $15,000 | +21.11% | |
Lisa Mcclain House | Oct 22, 2025 | Sep 25, 2025 | 27 days | SELL | $1,001 - $15,000 | +21.11% |
Novartis AG ADR (NVS) congressional trading FAQ
Can members of Congress legally trade Novartis AG ADR (NVS) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Novartis AG ADR (NVS), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; it does not imply any trade was improper.
Are congressional Novartis AG ADR (NVS) trades public?
Yes. Every congressional trade in Novartis AG ADR (NVS) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Novartis AG ADR (NVS)?
Members of Congress have disclosed 158 trades in Novartis AG ADR (NVS) worth $3M across 25 members, according to public STOCK Act filings.
Which members of Congress have traded Novartis AG ADR (NVS)?
Recent and active filers of Novartis AG ADR (NVS) disclosures include Lisa Mcclain, Ro Khanna. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Novartis AG ADR (NVS) more?
Across disclosed Novartis AG ADR (NVS) trades, 48% were by Democrats and 51% by Republicans, led by Republicans (51%).
What is the most recent congressional Novartis AG ADR (NVS) trade?
The most recent disclosed Novartis AG ADR (NVS) trade was a sale by Ro Khanna, filed Apr 6, 2026.
Browse all stocks Congress tradesCongressional trading overviewNovartis AG ADR (NVS) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.